Universal Health Services heads into its May 20 earnings report with a sharp, recent build in bearish positioning that has outpaced anything seen over the prior month.
Short interest is the standout story. SI has climbed to 5.2% of the free float — not extreme on its own — but the pace of accumulation is striking. Shares short rose 40% over the past week and are up 66% versus a month ago. The bulk of that move arrived in a single step: short positions jumped from roughly 2.1 million shares on May 8 to 2.85 million by May 11 and held near that level through mid-week. The ORTEX short score has tracked that shift, moving from the mid-36s to 42 over the same span. Cost to borrow remains cheap at 0.41%, and availability is still ample, meaning this is a deliberate positioning move rather than a technically-driven squeeze setup.
Options tell a different story from short interest. The put/call ratio has normalised sharply to 0.94 — well below its 20-day average of 3.44 — as the extreme hedging wave from late April has unwound. Through mid-April, UHS options were trading with a PCR near 12, a level close to the 52-week peak. That defensive crowding has since largely cleared. Bulls and bears in the options market appear to have reached something closer to parity heading into the print.
Analysts responded to the last quarterly release with broad target cuts but no rating downgrades. UBS trimmed to $310, Barclays to $238 (both maintaining positive ratings), and TD Cowen, Guggenheim, and Cantor Fitzgerald all reduced targets while keeping their calls unchanged. The Street's mean target of $223 sits roughly 32% above the current price of $168.64, implying the consensus still sees meaningful upside — but that gap also reflects how far the stock has fallen. The bull case centres on UHS's leadership in behavioural health and its ability to grow capacity in structurally undersupplied markets. The bear case points to labour cost pressure, regulatory execution risk, and lingering uncertainty around the Talkspace integration. At a trailing PE of 7.1 and an EV/EBITDA near 5.7, the valuation is undemanding — the EV/EBIT factor scores in the 95th percentile of the universe — but the low multiple has not been enough to arrest the stock's 7% decline over the past month.
The earnings history adds an important note: the two most recent prints each produced single-day declines of roughly 6.5-6.8%, with the weakness extending further over the following five sessions. With short interest having just made a significant one-week step-up into this release, Wednesday's print is less about whether UHS can hold its market position and more about whether the numbers — particularly on labour costs and behavioural health volumes — justify any rerating from a valuation floor that the market has not yet treated as a genuine catalyst.
See the live data behind this article on ORTEX.
Open UHS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
